INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2011

A health maintenance protocol with telomerase activator TA-65 reduced senescent cytotoxic T cells and the percentage of short telomeres over 1 year.

An analysis of the first year of data from a commercial health maintenance program (PattonProtocol-1) evaluated the effects of 10-50 mg daily of the telomerase activator TA-65 along with a dietary supplement pack and physician counseling. In vivo, there were significant declines in the percent of senescent cytotoxic (CD8(+)/CD28(-)) T cells at 6, 9, and 12 months (p = 0.018, 0.0024, and 0.0062) and natural killer cells at 6 and 12 months (p = 0.028 and 0.00013), mostly in CMV-seropositive subjects. In a subset measured at baseline and 12 months, mean telomere length did not increase, but the percent of short (<4 kbp) telomeres significantly decreased (p = 0.037). No adverse events were attributed to the protocol, and controlled randomized trials are planned to assess TA-65-specific effects.

Study type
Intervention study
Who was studied
Participants in a commercial health maintenance program (PattonProtocol-1)
What was measured
Immune cell proportions, telomere length distribution, and adverse events

THE PAPER

A natural product telomerase activator as part of a health maintenance program.

Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM. Rejuvenation Res, 2011.

PubMed 20822369 ↗DOI 10.1089/rej.2010.1085 ↗

Nutrients & adequacyHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.